Genetic testing for lung cancer after immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This study looks at the genetic makeup of lung cancer tumors after patients receive immunotherapy before surgery. It aims to understand why some tumors do not completely disappear and may help guide future treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have non-small cell lung cancer that was removed with surgery.
- You received immunotherapy before your surgery.
- Your tumor did not completely disappear after surgery (not a complete response).
- Your tumor does not have certain genetic changes (EGFR or ALK).
- You have stored tumor tissue samples available for testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well immunotherapy given before surgery works for non-small cell lung cancer. It aims to help doctors understand real-world outcomes for patients who receive this treatment.
This study looks at genetic material from tumor samples to find patterns that can predict whether immunotherapy will work for people with advanced non-small cell lung cancer (NSCLC). The goal is to improve how doctors choose treatments for each patient.
This study looks at how your immune system works in non-small cell lung cancer and whether it predicts how well you'll respond to a type of immunotherapy called anti-PD-1/PD-L1 drugs. Researchers will study your tumor tissue to understand why some patients benefit more than others.
This trial collects tissue samples from your lung tumor and any tumors that have spread to other parts of your body. They will study the genetic makeup of these samples to better understand lung cancer and improve future treatments.
This study collects and analyzes lung cancer tissue samples to understand genetic differences that may help guide future treatment. You'll provide a tissue sample (either from a biopsy or prior surgery), and researchers will study it—no treatment is given in this study.
This trial uses advanced gene sequencing technology on blood and tumor tissue samples from people with non-small cell lung cancer. The goal is to see if this testing can help doctors better predict which treatments will work and detect if the cancer comes back early.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.